Capricor Therapeutics (CAPR) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Capricor Therapeutics (CAPR) over the past year, gaining 11.8% versus a gain of 8.0%. Contineum Therapeutics is the larger company by market cap ($472.0 million vs $454.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | CTNM |
|---|---|---|
| Share price | $7.82 | $12.55 |
| Market cap | $454.36M | $471.96M |
| 1-day change | -3.52% | -1.45% |
| YTD return | -71.93% | +11.37% |
| 1-year return | +8.00% | +11.76% |
| 5-year return | +104.55% | — |
| EPS (TTM) | $-2.45 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.37 | $17.79 |
| 52-week low | $2.96 | $8.60 |
| Distance from 52-week high | -80.64% | -29.46% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +245.49% | +78.80% |
| Average volume | 6.85M | 502.82K |
| Shares outstanding | 58.14M | 32.96M |
| Employees | 231 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
CAPR vs CTNM FAQ
Which is bigger, Capricor Therapeutics or Contineum Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $471.96M compared with $454.36M for Capricor Therapeutics (CAPR).
Which stock has performed better over the past year, CAPR or CTNM?
CTNM returned +11.76% over the past 12 months, compared with +8.00% for CAPR (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.